Physician profile
Jim George
NPI 1619288230
$5,127.87
in general payments reported to CMS, 2019-2025
40 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $1,198 · 2021: $909 · 2022: $535 · 2023: $418 · 2024: $444 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $501.33 | 2019-2023 | Breztri |
| Abbvie INC. | $461.32 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $350.18 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Pfizer INC. | $342.19 | 2019-2025 | |
| Amarin Pharma, INC. | $311.58 | 2019-2022 | |
| Abbott Laboratories | $304.00 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $235.18 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.50 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.82 | 2019-2022 | |
| Amgen INC. | $141.43 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Sanofi-Aventis U.S. LLC | $129.03 | 2019-2023 | |
| Allergan, INC. | $106.42 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $103.57 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.22 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.